natgillin/translations-raw huggingface dataset:
After incubation for 10 minutes at room temperature with constant mixing, the plate was read with a luminometer, with the number of live cells being proportional to the observed luminescence. 
Nakon inkubacije od 10 minuta kod sobne temperature uz konstantno miješanje, ploča je očitana sa luminometrom, sa brojem živih stanica HR P20090134 T3 koji je proporcionalan luminiscentnom opažanju.
A pharmaceutical composition, comprising the monoclonal antibody or the antigen-binding portion according to any one of claims 1 to 9 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća monoklonalno protutijelo ili njegov dio koji se veže na antigen prema bilo kojem od zahtjeva 1 do 6 1 farmaceutski prihvatljiv nosač.
In a preferred embodiment the retentate of the permeate separation stage (3) is recycled without total decompression into an elevated compression stage of the compressor (4) and/or the permeate of the second stage is recycled into an elevated compression stage of the compressor (4). 
Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time da prva struja retentata (7) i/ili druga struja retentata (8) i/ili treća struja retentata (10) prolazi/prolaze kroz ventil za snižavanje tlaka.
Long chain fibres, e.g. 
Vlakna dugih lanaca, npr.
The mixture was evaporated to small volume and loaded onto silica gel column. The desired pure 2-acetyl-3-bromomethyl-4H,9H-naphtho[2,3-b]furan-4,9-dione 4-6 (R1═H, R3═CH3, R7═BrCH2) was obtained. 
Kombinacija iz patentnog zahtjeva 1, pri čemu je prvi agens 2-acetilnafto[2,3-b]furan-4,9-dion, a drugi agens je gemcitabin, pri čemu je prvi agens formuliran u sastavu koji sadrži Gelucire&.
The compound or a pharmaceutically acceptable salt thereof for use according to any of claims 17 to 18, wherein said use is in combination with at least one cognitive enhancing agent, memory enhancing agent, or choline esterase inhibitor. 
Spoj ili njegova farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 4 ili 5, naznačen time da je navedeno korištenje u kombinaciji s najmanje jednim sredstvom za poboljšavanje kognitivnih funkcija, sredstvom za pospješivanje pamćenja ili inhibitorom kolin esteraze.
The humanized CD37-specific binding protein of any of claims 1-8 or the composition of claim 10 for use in treating an autoimmune disease, wherein the autoimmune disease is rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Chron's disease, Sjogren's syndrome, Grave's disease, type I diabetes mellitus, psoriasis, immune thrombocytopenic purpura, pemphigus, idiopathic inflammatory myopathy, myasthenia gravis, or Waldenstorm's macroglobinemia. 
Humanizirani protein koji se specifično veže na CD37, ili protein koji se specifično veže na CD20, ili proizvodni artikl za upotrebu u liječenju karcinoma B-stanica ili autoimune bolesti navedeni u bilo kojem od patentnih zahtjeva 1 do 16, pri čemu je autoimuna bolest reumatoidni artritis, multipla skleroza, sustavni eritematozni lupus, Crohnova bolest, Sjogrenov sindrom, Graveova bolest, dijabetes melitus tipa I, psorijaza, idiopatska trombocitopenična purpura, pemfigus, idiopatska upalna miopatija, mijastenija gravis ili Waldernstormova makroglobulinemija.
In a preferred embodiment, in at least one, preferably both L groups, the atom that is directly bonded to X is a carbon, and at least one nitrogen atom is directly bonded to said carbon. 
Spoj prema bilo kojem prethodnom zahtjevu, naznačen time što u barem jednoj, a poželjno u obje L skupine, atom koji je izravno vezan za N je ugljik, i barem jedan dušikov atom je izravno vezan za navedeni ugljik.
The reaction was exothermic. 
Reakcija je egzotermna.
Desirably, if service of the apparatus is required it may be simply lifted from its floor or support surface and the various fluid connectors will be sealed by appropriate valves that close automatically when the housing is lifted. 
Po želji, ako je potrebno izvršiti servis ili popravak na uređaju, jednostavnim njegovim podizanjem s poda ili nosive površine automatski se zatvaraju priključci za fluide odgovarajućim ventilima.
The compound or the pharmaceutical composition for use according to claim 6, wherein said condition is selected from mood disorders, and further wherein said mood disorders are selected from depressive disorders or bipolar disorders. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 6, naznačen time što je navedeno stanje odabrano od poremećaja raspoloženja, i pri čemu su navedeni poremećaji raspoloženja dalje odabrani od depresivnih poremećaja 1li bipolarnih poremećaja.
A method for the treatment of infection by HIV or for the treatment of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 4 . 
Uporaba farmaceutskog pripravka prema bilo kojem od patentnih zahtjeva 1-6 za proizvodnju lijeka za profilaksu ili liječenje infekcije HIV-om ili za profilaksu, liječenje ili odgađanje početka SIDA-e kod subjekta kod kojeg postoji potreba za istim.
The buprenorphine dimer compound of claim 1, wherein the compound is in the form of a pharmaceutically acceptable salt. 
Dimer buprenorfina iz 1. patentnog zahtjeva, gdje spoj dolazi u obliku farmaceutski prihvatljive soli.
Vaccine comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein at least one fragment of said at least two fragments comprises at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID No. 9). 
Cjepivo, naznačeno time, da obuhvaća najmanje dva fragmenta proproteinske konvertaze subtilizin/keksin tipa 9 (PCSK9), pri čemu barem jedan od navedena najmanje dva fragmenta sadrže najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 153 do 165 od PCSK9 u skladu sa SEQ ID NO:9, i gdje barem jedan od navedena najmanje dva fragmenta sadrži najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 209 do 222 od PCSK9 u skladu sa SEQ ID NO:9.
The set as claimed in claim 1, wherein the mechanical locking system comprises a first locking strip, at the first or the second edge, provided with a first locking element configured to cooperate for horizontal locking with a first locking groove at the other of the first or second edge. 
Komplet prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što mehanički sustav zaključavanja sadrži prvu traku za zaključavanje (6), na prvom ili drugom rubu, opremljenu s prvim elementom za zaključavanje (8) konfiguriranim za zajedničko djelovanje radi vodoravnog zaključavanja s prvim utorom za zaključavanje (14) na drugom od prvog ili drugog ruba.
at least one substance which irritates the nasal passages and/or pharynx, 
(a) barem jednu tvar koja nadražuje šupljinu nosa i/ili ždrijela,
Thus, in a preferred aspect of the present invention the composition contains dimethylfumarate at a dose range of 125 mg to 500 mg and teriflunomide at a dose range of 1 mg to 6 mg. 
(b) dimetilfumarat u rasponu doze od 125 mg do 500 mg i lakvinimod u rasponu doze od 0,05 mg do 0,25 mg.
The garment according to claim 1, wherein the natural non-elastic fibre material is cotton. 
Odjevni predmet u skladu s patentnim zahtjevom 1, naznačen time, da je materijal od prirodnih neelastičnih vlakana pamuk.
The ultrasound system according to claim 1, wherein said fixture comprises a sliding track and a fixed track, and wherein said first tracking point is arranged on said fixed track, and wherein said second tracking point is arranged on said sliding track. 
Neuronavigacijski vođeni fokusirani ultrazvučni sustav prema zahtjevu 1, naznačen time što navedeni pribor za učvršćivanje obuhvaća kliznu tračnicu i nepomičnu tračnicu, te pri čemu je navedena prva točka praćenja postavljena na navedenu nepomičnu tračnicu, te pri čemu je navedena druga točka praćenja postavljena na navedenu kliznu tračnicu.
selecting an antibody producing cell which produces the antibody which binds to human ILT7 from the antibody producing cell of the immune animal; and culturing the antibody producing cell selected by step (2) and recovering an antibody capable of recognizing human ILT7 from the culture. 
proizvodnju i odabir stanice koja proizvodi protutijelo koja proizvodi protutijelo koje se veže na humani ILT7 iz stanice koja proizvodi protutijelo ne-humane životinje; te kultiviranje tako odabrane stanice i povrat monoklonskog protutijela iz kulture.
The duck cell of claim 1, wherein said paramyxovirus or recombinant paramyxovirus is selected in the group consisting of measles virus, mumps virus, rubella virus, Sendai virus, Respiratory Syncythial virus (RSV), human para-influenza types I and III, Rinderpest virus, canine distemper virus, Newcastle disease virus, duck para-influenza virus. 
paramiksovirus ili rekombinantni paramiksovirus izabran iz grupe koja obuhvaća virus ospica, virus zaušnjaka, rubela virus, Sendai virus, Respiratorni Sincicijski virus (RSV), humani para-influenca tipovi I i III, virus goveđe kuge, virus pseće kuge, virus Newcastle bolesti, virus pačje para-influence;
the number of individuals in which 
Broj međunarodne prijave:
As shown in Figure 1, the lid is composed of two components, but it is contemplated that a one-piece or multi-piece cap may also be used. 
Kako je prikazano na Slici 1, poklopac se sastoji od dva dijela, ali smatra se kako se također može koristiti poklopac u jednom dijelu ili višedijelni.
A pharmaceutical comprising the 1-thio-D-glucitol compound, the pharmaceutically acceptable salt thereof, or the hydrate of the compound or the salt according to any one of claims 1 to 17, in combination with at least one pharmaceutical selected from the group consisting of an insulin sensitizing agent, which is selected from the group consisting of a PPAR-Y agonist, a PPAR-a/Y agonist, a PPAR-δ agonist and a PPAR-a/Y/δ agonist; a glycosidase inhibitor; a biguanide; an insulin secretion accelerator; an insulin preparation; and a dipeptidyl peptidase IV inhibitor. 
Farmaceutski pripravak prema zahtjevu 21, naznačen time da nadalje sadrži najmanje jedno sredstvo za senzibilizaciju inzulina, koje je odabrano iz skupine koja sadrži PPAR-y agonist, PPAR-a/y agonist, PPAR-8 agonist i PPAR-a/y/8 agonist; inhibitor glukozidaze; bigvanid; akcelerator sekrecije inzulina; pripravak inzulina; i inhibitor dipeptidil peptidaze TV.
The pharmaceutical composition as claimed in claim 5, 7, 10 or 12, in which the host cell is an antigen-presenting cell. The pharmaceutical composition as claimed in claim 4, 5 or 7, in which the antibody is a monoclonal, chimeric or humanized antibody, or is a fragment of an antibody. 
Farmaceutska kompozicija prema patentnom zahtjevu 1 za uporabu u postupku za liječenje ili prevenciju kancera naznačenog ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 1, gdje je antitijelo monoklonalno, himerno ili humanizirano antitijelo, ili je fragment antitijela.
An empty pan was placed at the reference position. 
Prazna tava je postavljena na referentnu poziciju.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5ilamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
Next, Formula 42 was converted to a compound of Formula 43 according to the following reaction: 
Nakon toga je formula 42 konvertirana u spoj formule 43 prema sljedećoj reakciji: 9_Q4 ose,
Package according to anyone of claims 1 to 31, characterised in that the package comprises at least one of the materials included in the following list: cardboard, laminated cardboard, coated cardboard, cardboard in the weight range from 180 g/m2 to 290 g/m2, cardboard in the thickness range from 250 µm to 500 µm, cardboard in the stiffness range from 5 mN to 25 mN, flat material in the thickness range from 50 µm to 2000 µm, plastics materials, metals, aluminium. 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 31, naznačen time što omot za pakiranje sadržava najmanje jedan od materijala koji su uključeni u sljedeći popis materijala: karton, laminirani karton, karton prekriven slojem, karton koji ima masu u području od 180 g/m2 do 290 g/m2, karton koji ima debljinu u području od 250 um do 500 um, karton koji ima krutost u području od 5 mN do 25 mN, plosnati materijal koji ima debljinu u području od 50 um do 2000 um, plastični materijal, metali, aluminij.
is selected from phenyl, substituted phenyl, benzyl, substituted benzyl, biphenyl, substituted biphenyl, biphenylmethylene, substituted biphenylmethylene, naphthyl, substituted naphthyl, naphthylmethylene, and substituted naphthylmethylene, or a pharmaceutically compatible salt thereof. 
je odabran od fenila, supstituiranog fenila, benzila, supstituiranog benzila, bifenila, supstituiranog bifenila, bifenilmetilena, supstituiranog bifenilmetilena, naftila, supstituiranog naftila, naftilmetilena, i supstituiranog naftilmetilena, ili njihova farmaceutski kompatibilna sol.
Therefore, the liver serves as an important buffer for the plasma glucose level and glycogen phosphorylase is positioned at a critical juncture for the reciprocal regulation of glucose metabolism. 
Stoga, jetra služi kao važni pufer za razinu glukoze u plazmi i glikogen fosforilaza se nalazi na kritičnoj vezi recipročne regulacije metabolizma glukoze.
is selected from Ala and Glu; 
X24 je odabran od Ala i Glu;
The solid dispersion of any of claims 1 to 7, wherein the N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide is present in an amount of from 10% by weight to 80% by weight. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1-3, gdje je amorfni N-[2,4-bis(1,11-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksokinolin-3-karboksamid u obliku čvrste disperzije.
An indolizine derivative as claimed in claim 3 or 4, wherein R2a and R2b independently represent any of the following (b1) to (b4): 
Derivat indolizina prema zahtjevu 3 ili 4, gdje R* i R* nezavisno predstavljaju bilo što od sljedećeg (b1) do (b4):
at least 12 hVλ gene segments; or to 28 or more hVλ gene segments. 
(a) najmanje 12 nepreuređenih humanih segmenata gena V2; ili
Compounds of formula (1) may be prepared by reaction of the carboxylic acid (11, wherein R1, R2 and R3 have the meanings defined in formula 1). 
Spojeve formule (1) može se dobiti reakcijom karboksilne kiseline (11), gdje Ri, R2 i Rz znače kao što je definirano za formulu (1)
Known solutions provide for the incorporation of the organic component for the renewal of humus in combination with the mineral component of the fertilizer, which is a source of N, P₂O₅ and K₂O; they have, however, several disadvantages. 
Inače, poznata rješenja omogućuju unašanje organske komponente za obnavljanje humusa u tlima zajedno s mineralnom komponentom gnojiva, koja je izvor N, P=P205 i K20. Premda 1 ta rješenja imaju više nedostataka.
The patient in need of such administration is a patient suffering from or exhibiting, or at risk of suffering from or exhibiting, one or more psychoses, for example a psychosis characteristic of schizophrenia. 
Pacijent kojemu je potrebna takva primjena je obično pacijent koji pati od ili koji pokazuje, ili kod kojeg postoji rizik da će patiti od ili da će pokazivati, jednu ili više psihoza, na primjer psihozu karakterističnu za šizofreniju.
wherein R7 is substituted or unsubstituted (C1-C6) alkyl or a (C3-C6) cycloalkyl or cycloheteroalkyl; n is 2, 3, 4, or 5; wherein a substituted aryl or heteroaryl group can be substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, carboxylate, alkylcarbonyl, cyano, amino, acylamino, sulfhydryl, alkylthio, arylthio, nitro, trifluoromethyl and cyano; and wherein a substituted alkyl may be substituted by one or more substituents selected from the group consisting of alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonyloxy; alkynyl, alkylcarbonyl, alkylthio, alkythiocarbonyl, thiocarboxylate, arylthio, arylcarbonyl, arylcarbonyloxy, acylamino, carboxylate, cyano, halogen, haloalkyl, cycloalkoxy, acetamide, amine, hydroxyl, nitro, sulfhydryl, sulfonamido and trifluoromethyl; 
R;-alkoksi; R;-haloalkil; ili R»-haloalkoksi; pri čemu R; je supstituirani ili nesupstituirani (Ci-Cg) alkil ili (C3-Cg) cikloalkil ili cikloheteroalkil; n je 2, 3, 4 ili 5; gdje supstituirana aril ili heteroaril skupina može biti supstituirana s jednim ili više supstituenata odabranih iz skupine koja se sastoji od halogena, hidroksila, alkoksila, = alkilkarboniloksija, = arilkarboniloksija, alkoksikarboniloksija, karboksilata, alkilkarbonila, cijano, amino, acilamino, sulfhidrila, alkiltio, nitro, trifluorometila i cijano; i gdje supstituirani alkil može biti supstituiran s jednim ili više supstituenata odabranih iz skupine koja se sastoji od alkenila, alkoksija, alkoksikarbonila, alkoksikarboniloksija; alkinila, alkilkarbonila, alkiltio, alkiltiokarbonila, tiokarboksimida, amina, hidroksila, nitro, sulfhidrila, sulfonamida i trifluorometila; ili njihove farmaceutski prihvatljive soli i/ili estera.
assaying a subject sample, wherein the subject is a human subject with FLT3 mutated acute myeloid leukemia (AML); determining which receptor tyrosine kinases are deregulated; and administering to said subject a therapeutically effective amount of the composition if the deregulated receptor tyrosine kinase is a FLT3 receptor tyrosine kinase, wherein the composition specifically inhibits the kinase. 
Pripravak koji sadrži crenolanib ili njegovu sol namijenjen uporabi u liječenju deregulirane receptorske tirozin kinaze sadrži: ispitivanje predmetnog uzorka, pri čemu je subjekt osoba s FLT3 mutiranom akutnom mijeloičnom leukemijom (AML); određivanje koje se receptorske tirozinske kinaze dereguliraju; i davanje spomenutom subjektu terapeutski djelotvorne količine pripravka ako je deregulirana receptorska tirozinska kinaza FLT3 receptorska tirozinska kinaza, pri čemu pripravak posebice mhibira kinazu.
Finally, there is a need for methods of treating patients with such compounds for use in cancer treatment regimens. 
Na kraju, potrebni su postupci liječenja pacijenata s takvim pripravcima za upotrebu u režimima liječenja karcinoma.
Primary recovery of IL-2 included concentration, cell disruption, diafiltration, inactivation, redisruption and sucrose suspension. 
Primarno dobivanje IL-2 je uključilo je koncentraciju, razbijanje stanica, diafiltraciju, inaktivaciju, ponovno razbijanje i suspenziju u saharozi.
hydrogenating the acid salt to form (S)-3-aminomethyl-5-methylhexanoic acid (pregabalin). 
(d) hidrogeniranja kisele soli kako bi se dobilo (S)-3-aminometil-5-metilheksansku kiselinu (pregabalin).
The process according to claim 1, wherein the compound of formula II' is prepared by comprising the steps of either (0-1) providing a compound of formula I wherein Pg is an amino protecting group, and 
[image] gdje Pg je amino-zaštitna skupina, i (1-2) reakcija spoja formule I sa spojem sljedeće formule:
In typical embodiments, the pharmaceutical composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous or subcutaneous administration to human beings. 
Protutijelo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 2-5, naznačeno time što se navedeno protutijelo primjenjuje parenteralnim načinom, intravenskim načinom ili supkutanim načinom primjene.
• when RCG1 represents a O-alkyl hydroxylamine function or a Pictet-Spengler reaction substrate, RCG2 represents an aldehyde or ketone function. 
• kada RCG1 predstavlja O-alkil hidroksilaminsku funkciju ili Pictet-Spengler reakcijski supstrat, RCG2 predstavlja aldehidnu ili ketonsku funkciju.
the second fragment is a toxin B repeating domain fragment and comprises at least 100 amino acids; 
drugi fragment je fragment ponavljajuće domene toksina B;
The humanized anti-CD40 antibody for use as in claim 5, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, proliferative lupus glomerulonephritis, inflammatory bowel disease (IBD), psoriasis, idiopathic thrombocytopenic purpura (ITP), Crohn's Disease and systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, primary myxoedema, thyrotoxicosis/Graves disease, pernicious anaemia, autoimmune atrophic gastritis, autoimmune carditis, Addison's disease, premature menopause, type 1-diabetes mellitus, Good pasture's syndrome, myasthenia gravis, autoimmune haemolytic anaemia, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis (HBs Ag negative), cryptogenic cirrhosis, Sjogren's syndrome, dermatomyositis, scleroderma, mixed tissues connective disease, discoid lupus erythematosus, and systemic vasculitis. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 3, naznačeno time što se autoimunu ili upalnu bolest bira iz skupine koju čine reumatoidni artritis, multipla skleroza, proliferativni lupus s glomerulonefritisom, upalna bolest crijeva (IBD), psorijaza, idiopatska trombocitopenična purpura (ITP), Crohnova bolest i sistemni eritematozni lupus (SLE), Hashimotoov tireoiditis, primarni miksoedem, tirotoksikoza/Gravesova bolest, perniciozna anemija, autoimuni atrofični gastritis, autoimuni karditis, Addisonova bolest, prijevremena menopauza, dijabetes melitus tip 1, Goodpastureov sindrom, mijastenija gravis, autoimuna hemolitična anemija, idiopatska leukopenija, primarna bilijarna ciroza, aktivni kronični hepatitis (HBs Ag negativni), kriptogena ciroza, Sjogrenov sindrom, dermatomiozitis, skleroderma, miješana bolest vezivnih tkiva, diskoidni eritematozni lupus, te sistemni vaskulitis.
Process according to any of claims 1 to 3 in which the melt is withdrawn for further downstream processing, including flat glass or container glass formation, continuous fiber formation or mineral wool fiber production. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se talinu izvlači radi dodatne daljnje obrade, uključujući dobivanje ravnog stakla ili stakla za spremnike, dobivanje kontinuiranih vlakana ili proizvodnju vlakana za mineralnu vunu.
To prepare emulsions, pastes or oil dispersions, the substances, as such or dissolved in an oil or solvent, can be homogenized in water by means of wetting agent, tackifier, dispersant or emulsifier. 
Za pripremu emulzija, pasta ili uljnih disperzija, supstance, kao takve ili otopljene u ulju ili otapalu, mogu biti homogenizirane u vodi dodavanjem sredstva za vlaženje, sredstva za zgušnjavanje, raspršivog sredstva ili emulgatora.
or a pharmaceutically acceptable salt, stereoisomer and/or solvate thereof; or 
=N ili njena farmaceutski prihvatljiva sol, stereoizomer i/ili solvat.
A solution currently applied is to produce small homogeneous batches (about 1000 kg) of ground scrap (PMMA and/or ABS): each batch is subjected to an extrusion test to check for the presence or absence of crosslinked PMMA. 
Rješenje koje se danas primjenjuje je proizvodnja malih homogenih hrpa (oko 1000 kg) mljevenog otpada (PMMA i/ili BSA): svaka hrpa se podvrgava testu ekstruzije da bi se ispitala prisutnost ili odsutnost umreženog PMMA.
The solution is dried (Na2SO4), filtered, and concentrated in vacuo to yield 12.4 g (92%). 
Otopinu se osuši (Na»SO,), filtrira, te koncentrira u vakuumu kako bi se dobilo 12,4 g HR P20070422 T3
reacting an intermediate of formula (II) with an intermediate of formula (III) wherein W is an appropriate leaving group such as, for example, halo, wherein the variables are as defined in claim 1; 
a) reakciju međuprodukta formule (II) sa međuproduktom formule (III) pri čemu W je prikladna odlazna skupina kao što je, na primjer, halo,! 2 R*-Q
The pharmaceutical composition of Claim 22, wherein the therapeutic agent is an AT1 receptor antagonist. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 22, naznačen time, da je terapijsko sredstvo antagonist receptora AT].
Brief description of the figures 
Kratak opis slika